American Century Companies’s Kymera Therapeutics KYMR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$940K Buy
+8,196
New +$704K ﹤0.01% 2415
2026
Q1
– Sell
-2,819
Closed -$219K – 2888
2025
Q4
$219K Buy
+2,819
New +$190K ﹤0.01% 2692
2024
Q4
– Sell
-9,298
Closed -$440K – 2924
2024
Q3
$440K Sell
9,298
-1,549
-14% -$68.4K ﹤0.01% 2517
2024
Q2
$324K Sell
10,847
-36,820
-77% -$1.27M ﹤0.01% 2593
2024
Q1
$1.92M Buy
47,667
+24,893
+109% +$891K ﹤0.01% 1902
2023
Q4
$580K Sell
22,774
-211,784
-90% -$3.79M ﹤0.01% 2312
2023
Q3
$3.26M Buy
234,558
+124,005
+112% +$2.49M ﹤0.01% 1499
2023
Q2
$2.54M Sell
110,553
-4,489
-4% -$129K ﹤0.01% 1566
2023
Q1
$3.4M Buy
115,042
+4,328
+4% +$140K ﹤0.01% 1404
2022
Q4
$2.76M Sell
110,714
-117,496
-51% -$3.13M ﹤0.01% 1456
2022
Q3
$4.97M Buy
228,210
+1,351
+0.6% +$35.6K ﹤0.01% 1108
2022
Q2
$4.47M Buy
226,859
+13,899
+7% +$325K ﹤0.01% 1146
2022
Q1
$9.01M Buy
212,960
+25,933
+14% +$1.1M 0.01% 944
2021
Q4
$11.9M Buy
187,027
+36,281
+24% +$2.11M 0.01% 835
2021
Q3
$8.86M Buy
150,746
+52
+0% +$3.02K 0.01% 878
2021
Q2
$7.31M Buy
150,694
+362
+0.2% +$15.7K 0.01% 896
2021
Q1
$5.84M Sell
150,332
-1,243
-0.8% -$74.8K ﹤0.01% 898
2020
Q4
$9.4M Sell
151,575
-198
-0.1% -$9.66K 0.01% 776
2020
Q3
$4.9M Buy
+151,773
New +$4.63M ﹤0.01% 806

Other funds holding KYMR

American Century Companies's KYMR Position: Q2 2026 in Review

American Century Companies opened a new position in Kymera Therapeutics (KYMR) in Q2 2026: 8,196 shares worth $940K. The stake represents ﹤0.01% of the portfolio and ranks #2415 among its holdings. This is a return to the name: American Century Companies previously reported a position in KYMR as recently as Q4 2025.

American Century Companies first reported a position in KYMR in Q3 2020 and has held it in 19 quarters since. The position peaked at $11.9M in Q4 2021. 276 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • American Century Companies held 8,196 shares of Kymera Therapeutics worth $940K as of Q2 2026.
  • Kymera Therapeutics was a new American Century Companies position in Q2 2026.
  • Kymera Therapeutics made up ﹤0.01% of American Century Companies's portfolio in Q2 2026, its #2415 holding.
  • American Century Companies first reported a position in Kymera Therapeutics in Q3 2020 and has held it in 19 quarters since.
  • American Century Companies's Kymera Therapeutics position peaked at $11.9M in Q4 2021.
  • 276 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on American Century Companies's 13F filing for Q2 2026, filed 12 Aug 2026.